Personal information

Other IDs

SciProfiles: 2358718
Scopus Author ID: 55220238600

Activities

Collapse all

Employment (1)

The University of Texas MD Anderson Cancer Center: Houston, Texas, US

Principal Research Scientist (Investigational Cancer Therapeutics)
Employment
Source: Self-asserted source
Bettzy Stephen

Works (49)

A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers

Cancer
2025-02 | Journal article
DOI: 10.1002/cncr.35728
Contributors: Jibran Ahmed; Filip Janku; Daniel D. Karp; Sarina A. Piha‐Paul; Apostolia M. Tsimberidou; Timothy Anthony Yap; Bettzy Stephen; Yali Yang; Serdar Gurses; Qian Liu et al.
Source: check_circle
Crossref

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine
2025-02 | Journal article
DOI: 10.1002/cam4.70280
Contributors: Omar Alhalabi; Mohamed A. Gouda; Denái R. Milton; Hassan Ahmed Momin; Bulent Yilmaz; Bettzy Stephen; Chinenye Lynette Ejezie; Justin Tyler Moyers; Serdar A. Gurses; Jeffrey How et al.
Source: check_circle
Crossref

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer
2024-02 | Journal article
DOI: 10.1002/cncr.35063
Contributors: Anne Knisely; Jibran Ahmed; Bettzy Stephen; Sarina A. Piha‐Paul; Daniel Karp; Abdulrazzak Zarifa; Siqing Fu; David Sanghyun Hong; Jordi Rodon Ahnert; Timothy A. Yap et al.
Source: check_circle
Crossref

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

Cancer Medicine
2024-02 | Journal article
DOI: 10.1002/cam4.6877
Contributors: Niamh Coleman; Bettzy Stephen; Siqing Fu; Daniel Karp; Vivek Subbiah; Jordi Rodon Ahnert; Sarina A. Piha‐Paul; John Wright; Senait N. Fessahaye; Fengying Ouyang et al.
Source: check_circle
Crossref

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

Cancer
2023-09 | Journal article
DOI: 10.1002/cncr.34820
Contributors: Mehmet Altan; Janet Tu; Denái R. Milton; Bulent Yilmaz; Yanyan Tian; Frank V. Fossella; Frank E. Mott; George R. Blumenschein; Bettzy Stephen; Daniel D. Karp et al.
Source: check_circle
Crossref

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma

Cancers
2023-07-27 | Journal article
DOI: 10.3390/cancers15153806
Contributors: Chijioke Nze; Pavlos Msaouel; Mohamed H. Derbala; Bettzy Stephen; Abdulrahman Abonofal; Funda Meric-Bernstam; Nizar M. Tannir; Aung Naing
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors

Journal of Immunotherapy and Precision Oncology
2023-05-01 | Journal article
DOI: 10.36401/JIPO-22-27
Contributors: Zainab Fatima; Abdulrahman Abonofal; Bettzy Stephen
Source: check_circle
Crossref

Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study

Cancer
2022 | Journal article
DOI: 10.1002/cncr.34370
EID:

2-s2.0-85133466206

Part of ISSN: 10970142 0008543X
Contributors: Ravi, V.; Subramaniam, A.; Zheng, J.; Amini, B.; Trinh, V.A.; Joseph, J.; Mennel, R.G.; Bishop, A.J.; Sturgis, E.M.; Goepfert, R.P. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study (Investigational New Drugs, (2022), 40, 2, (290-299), 10.1007/s10637-021-01188-1)

Investigational New Drugs
2022 | Journal article
DOI: 10.1007/s10637-021-01194-3
EID:

2-s2.0-85118527883

Part of ISSN: 15730646 01676997
Contributors: Thein, K.Z.; Karp, D.D.; Tsimberidou, A.; Gong, J.; Sulovic, S.; Shah, J.; Milton, D.R.; Hong, D.S.; Janku, F.; McQuinn, L. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): A phase 2 non-randomized clinical trial

Journal for ImmunoTherapy of Cancer
2022 | Journal article
DOI: 10.1136/jitc-2022-004822
EID:

2-s2.0-85130877126

Part of ISSN: 20511426
Contributors: Raghav, K.P.; Stephen, B.; Karp, D.D.; Piha-Paul, S.A.; Hong, D.S.; Jain, D.; Chudy Onwugaje, D.O.; Abonofal, A.; Willett, A.F.; Overman, M. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Safety and efficacy of immune checkpoint inhibitors in patients with cancer and viral hepatitis: The MD Anderson Cancer Center experience

ResearchSquare
2022 | Other
DOI: 10.21203/rs.3.rs-1902983
EID:

2-s2.0-85138359190
Contributors: Nardo, M.; Yilmaz, B.; Nelson, B.E.; Torres, H.A.; Wang, L.S.; Granwehr, B.P.; Song, J.; Pria, H.R.F.D.; Trinh, V.A.; Glitza Oliva, I.C. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

Investigational New Drugs
2022 | Journal article
DOI: 10.1007/s10637-021-01188-1
EID:

2-s2.0-85115716426

Part of ISSN: 15730646 01676997
Contributors: Thein, K.Z.; Karp, D.D.; Tsimberidou, A.; Gong, J.; Sulovic, S.; Shah, J.; Milton, D.R.; Hong, D.S.; Janku, F.; McQuinn, L. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

Journal of Immunotherapy and Precision Oncology
2022 | Journal article
DOI: 10.36401/JIPO-21-20
EID:

2-s2.0-85131644726

Part of ISSN: 2590017X 26662345
Contributors: Thein, K.Z.; Fu, S.; Janku, F.; Tsimberidou, A.M.; Piha-Paul, S.A.; Karp, D.D.; Shah, J.; Milton, D.R.; Gong, J.; Sulovic, S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials

Critical Reviews in Oncology/Hematology
2022 | Journal article
DOI: 10.1016/j.critrevonc.2022.103700
EID:

2-s2.0-85129909112

Part of ISSN: 18790461 10408428
Contributors: Guven, D.C.; Stephen, B.; Sahin, T.K.; Cakir, I.Y.; Erul, E.; Aksoy, S.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports
2022-08-23 | Journal article
DOI: 10.1038/s41598-022-16588-3
Contributors: Tito R. Mendoza; David S. Hong; Christine B. Peterson; Bettzy Stephen; Ecaterina Dumbrava; Shubbam Pant; Apostolia Maria Tsimberidou; Timothy Anthony Yap; Ajay Sheshadri; Mehmet Altan et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

Cancers
2022-07-29 | Journal article
DOI: 10.3390/cancers14153695
Contributors: Jeffrey A. How; Amir A. Jazaeri; Siqing Fu; Jordi Rodon Ahnert; Jing Gong; Bettzy Stephen; Hanna Ferreira Dalla Pria; Priya Bhosale; Amber Johnson; Ying Yuan et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Author response to Cunha et al

Journal for ImmunoTherapy of Cancer
2021 | Journal article
DOI: 10.1136/jitc-2021-003299
EID:

2-s2.0-85111724733

Part of ISSN: 20511426
Contributors: Colen, R.R.; Rolfo, C.; Ak, M.; Ayoub, M.; Ahmed, S.; Elshafeey, N.; Mamindla, P.; Zinn, P.O.; Ng, C.; Vikram, R. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial

Investigational New Drugs
2021 | Journal article
DOI: 10.1007/s10637-021-01074-w
EID:

2-s2.0-85101462090

Part of ISSN: 15730646 01676997
Contributors: Alshawa, A.; Cadena, A.P.; Stephen, B.; Reddy, A.; Mendoza, T.R.; McQuinn, L.; Lawhorn, K.; Zarifa, A.; Bernhardt, A.M.; Fessaheye, S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Immune System in Action

Advances in Experimental Medicine and Biology
2021 | Book chapter
DOI: 10.1007/978-3-030-79308-1_1
EID:

2-s2.0-85122480731

Part of ISSN: 22148019 00652598
Contributors: Stephen, B.; Hajjar, J.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens

Journal of Immunotherapy and Precision Oncology
2021 | Journal article
DOI: 10.36401/JIPO-21-5
EID:

2-s2.0-85107173232

Part of ISSN: 2590017X 26662345
Contributors: Xu, M.; Tapia, C.; Hajjar, J.; Sabir, S.; Colen, R.; Nagarajan, P.; Aung, P.P.; Gong, J.; Rodon, J.; Fu, S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial

Investigational New Drugs
2021 | Journal article
DOI: 10.1007/s10637-021-01100-x
EID:

2-s2.0-85103358273

Part of ISSN: 15730646 01676997
Contributors: Hahn, A.W.; Chahoud, J.; Campbell, M.T.; Karp, D.D.; Wang, J.; Stephen, B.; Tu, S.-M.; Pettaway, C.A.; Naing, A.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

Advances in Therapy
2021 | Journal article
DOI: 10.1007/s12325-021-01807-6
EID:

2-s2.0-85109871476

Part of ISSN: 18658652 0741238X
Contributors: Ferrarotto, R.; Sousa, L.G.; Qing, Y.; Kaya, D.; Stephen, B.; Jain, D.; Bell, D.; Pant, S.; Tsimberidou, A.M.; Janku, F. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer
2021 | Journal article
DOI: 10.1136/jitc-2020-001752
EID:

2-s2.0-85104155448

Part of ISSN: 20511426
Contributors: Colen, R.R.; Rolfo, C.; Ak, M.; Ayoub, M.; Ahmed, S.; Elshafeey, N.; Mamindla, P.; Zinn, P.O.; Ng, C.; Vikram, R. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

Investigational New Drugs
2021 | Journal article
DOI: 10.1007/s10637-020-01043-9
EID:

2-s2.0-85099088774

Part of ISSN: 15730646 01676997
Contributors: How, J.A.; Jazaeri, A.; Westin, S.N.; Sood, A.K.; Ramondetta, L.M.; Xu, M.; Abonofal, A.; Karp, D.D.; Subbiah, V.; Stephen, B. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Scientific Reports
2021-02-11 | Journal article
DOI: 10.1038/s41598-021-83317-7
Contributors: Jeffrey A. How; Amir A. Jazaeri; Pamela T. Soliman; Nicole D. Fleming; Jing Gong; Sarina A. Piha-Paul; Filip Janku; Bettzy Stephen; Aung Naing
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors

Journal for ImmunoTherapy of Cancer
2020 | Journal article
DOI: 10.1136/jitc-2020-000665
EID:

2-s2.0-85083755151

Part of ISSN: 20511426
Contributors: Tapia, C.; Aung, P.P.; Roy-Chowdhuri, S.; Xu, M.; Ouyang, F.; Alshawa, A.; Hajjar, J.; Singh, G.; Yang, V.; Castillo, L. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

Journal for ImmunoTherapy of Cancer
2020 | Journal article
DOI: 10.1136/jitc-2020-000931
EID:

2-s2.0-85094685112

Part of ISSN: 20511426
Contributors: Sheshadri, A.; Altan, M.; Hess, K.; George, G.; Stephen, B.; Castillo, L.; Rodriguez, E.; Gong, J.; Peterson, C.; Rodon Ahnert, J. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Overview of Basic Immunology and Clinical Application

Advances in Experimental Medicine and Biology
2020 | Book chapter
DOI: 10.1007/978-3-030-41008-7_1
EID:

2-s2.0-85083631832

Part of ISSN: 22148019 00652598
Contributors: Stephen, B.; Hajjar, J.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for immunotherapy of cancer
2020 | Journal article
DOI: 10.1136/jitc-2019-000347
EID:

2-s2.0-85081994525

Part of ISSN: 20511426
Contributors: Naing, A.; Meric-Bernstam, F.; Stephen, B.; Karp, D.D.; Hajjar, J.; Rodon Ahnert, J.; Piha-Paul, S.A.; Colen, R.R.; Jimenez, C.; Raghav, K.P. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas

Cancers
2020 | Journal article
DOI: 10.3390/cancers12082307
EID:

2-s2.0-85090255139

Part of ISSN: 20726694
Contributors: Jimenez, C.; Subbiah, V.; Stephen, B.; Ma, J.; Milton, D.; Xu, M.; Zarifa, A.; Akhmedzhanov, F.O.; Tsimberidou, A.; Habra, M.A. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers

SSRN
2019 | Other
DOI: 10.2139/ssrn.3396028
EID:

2-s2.0-85116433670

Part of ISSN: 15565068
Contributors: Naing, A.; Meric-Bernstam, F.; Stephen, B.; Karp, D.D.; Hajjar, J.; Ahnert, J.R.; Piha-Paul, S.A.; Colen, R.R.; Jimenez, C.; Raghav, K.P. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors

European Journal of Immunology
2019 | Journal article
DOI: 10.1002/eji.201948217
EID:

2-s2.0-85074420974

Part of ISSN: 15214141 00142980
Contributors: Creasy, C.A.; Forget, M.-A.; Singh, G.; Tapia, C.; Xu, M.; Stephen, B.; Sabir, S.; Meric-Bernstam, F.; Haymaker, C.; Bernatchez, C. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Haplotype analysis of the t-cell receptor beta (Tcrb) locus by long-amplicon tcrb repertoire sequencing

Journal of Immunotherapy and Precision Oncology
2019 | Journal article
DOI: 10.4103/JIPO.JIPO_16_19
EID:

2-s2.0-85096201681

Part of ISSN: 2590017X 26662345
Contributors: Looney, T.J.; Duose, D.Y.; Lowman, G.; Linch, E.; Hajjar, J.; Topacio-Hall, D.; Xu, M.; Zheng, J.; Alshawa, A.; Tapia, C. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Journal for ImmunoTherapy of Cancer
2019 | Journal article
DOI: 10.1186/s40425-019-0722-x
EID:

2-s2.0-85072391766

Part of ISSN: 20511426
Contributors: Habra, M.A.; Stephen, B.; Campbell, M.; Hess, K.; Tapia, C.; Xu, M.; Rodon Ahnert, J.; Jimenez, C.; Lee, J.E.; Perrier, N.D. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Haplotype Analysis of the TRB Locus by TCRB Repertoire Sequencing

bioRxiv
2018 | Other
DOI: 10.1101/406157
EID:

2-s2.0-85095642377

Part of ISSN: 26928205
Contributors: Looney, T.J.; Duose, D.Y.; Lowman, G.; Linch, E.; Hajjar, J.; Topacio-Hall, D.; Xu, M.; Zheng, J.; Alshawa, A.; Tapia, C. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Investigational New Drugs
2018 | Journal article
DOI: 10.1007/s10637-017-0534-0
EID:

2-s2.0-85034569859

Part of ISSN: 15730646 01676997
Contributors: Fujii, T.; Colen, R.R.; Bilen, M.A.; Hess, K.R.; Hajjar, J.; Suarez-Almazor, M.E.; Alshawa, A.; Hong, D.S.; Tsimberidou, A.; Janku, F. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Overview of basic immunology and translational relevance for clinical investigators

Advances in Experimental Medicine and Biology
2018 | Book chapter
DOI: 10.1007/978-3-030-02505-2_1
EID:

2-s2.0-85058592416

Part of ISSN: 22148019 00652598
Contributors: Stephen, B.; Hajjar, J.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

Investigational New Drugs
2018 | Journal article
DOI: 10.1007/s10637-017-0524-2
EID:

2-s2.0-85032392480

Part of ISSN: 15730646 01676997
Contributors: Colen, R.R.; Fujii, T.; Bilen, M.A.; Kotrotsou, A.; Abrol, S.; Hess, K.R.; Hajjar, J.; Suarez-Almazor, M.E.; Alshawa, A.; Hong, D.S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience

Investigational New Drugs
2017 | Journal article
DOI: 10.1007/s10637-016-0395-y
EID:

2-s2.0-84989159342

Part of ISSN: 15730646 01676997
Contributors: Bupathi, M.; Hajjar, J.; Bean, S.; Fu, S.; Hong, D.; Karp, D.; Stephen, B.; Hess, K.; Meric-Bernstam, F.; Naing, A.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Overview of basic immunology for clinical investigators

Advances in Experimental Medicine and Biology
2017 | Book chapter
DOI: 10.1007/978-3-319-53156-4_1
EID:

2-s2.0-85015968438

Part of ISSN: 22148019 00652598
Contributors: Stephen, B.; Hajjar, J.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Cancer therapy directed by comprehensive genomic profiling: A single center study

Cancer Research
2016 | Journal article
DOI: 10.1158/0008-5472.CAN-15-3043
EID:

2-s2.0-84977530459

Part of ISSN: 15387445 00085472
Contributors: Wheler, J.J.; Janku, F.; Naing, A.; Li, Y.; Stephen, B.; Zinner, R.; Subbiah, V.; Fu, S.; Karp, D.; Falchook, G.S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

TP53 alterations correlate with response to VEGF/VEGFR inhibitors: Implications for targeted therapeutics

Molecular Cancer Therapeutics
2016 | Journal article
DOI: 10.1158/1535-7163.MCT-16-0196
EID:

2-s2.0-84990927257

Part of ISSN: 15388514 15357163
Contributors: Wheler, J.J.; Janku, F.; Naing, A.; Li, Y.; Stephen, B.; Zinner, R.; Subbiah, V.; Fu, S.; Karp, D.; Falchook, G.S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Phase i combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

Investigational New Drugs
2015 | Journal article
DOI: 10.1007/s10637-015-0238-2
EID:

2-s2.0-84937758561

Part of ISSN: 15730646 01676997
Contributors: Rodrigues, H.V.; Ke, D.; Lim, J.; Stephen, B.; Bellido, J.; Janku, F.; Zinner, R.; Tsimberidou, A.; Hong, D.; Piha-Paul, S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: Improved outcomes with combination chemotherapy and targeted agents

Molecular Cancer Therapeutics
2014 | Journal article
DOI: 10.1158/1535-7163.MCT-14-0358
EID:

2-s2.0-84918500160

Part of ISSN: 15388514 15357163
Contributors: Ganesan, P.; Moulder, S.; Lee, J.J.; Janku, F.; Valero, V.; Zinner, R.G.; Naing, A.; Fu, S.; Tsimberidou, A.M.; Hong, D. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: Implications for therapy

Annals of Oncology
2013 | Journal article
DOI: 10.1093/annonc/mds524
EID:

2-s2.0-84874564640

Part of ISSN: 09237534 15698041
Contributors: Wheler, J.J.; Falchook, G.S.; Tsimberidou, A.M.; Hong, D.S.; Naing, A.; Piha-Paul, S.A.; Chen, S.S.; Fu, S.; Stephen, B.; Fok, J.Y. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: A retrospective analysis of an MD Anderson Cancer Center phase I population

Oncotarget
2013 | Journal article
DOI: 10.18632/oncotarget.1028
EID:

2-s2.0-84880303931

Part of ISSN: 19492553
Contributors: Wheler, J.; Falchook, G.; Tsimberidou, A.M.; Hong, D.; Naing, A.; Piha-Paul, S.; Chen, S.S.; Heymach, J.; Fu, S.; Stephen, B. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Thymoma patients treated in a phase I clinic at MD anderson cancer center: Responses to mTOR inhibitors and molecular analyses

Oncotarget
2013 | Journal article
DOI: 10.18632/oncotarget.1015
EID:

2-s2.0-84880780127

Part of ISSN: 19492553
Contributors: Wheler, J.; Hong, D.; Swisher, S.G.; Falchook, G.; Tsimberidou, A.M.; Helgason, T.; Naing, A.; Stephen, B.; Janku, F.; Stephens, P.J. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: The M. D. anderson cancer center experience

Annals of Oncology
2012 | Journal article
DOI: 10.1093/annonc/mds027
EID:

2-s2.0-84864939835

Part of ISSN: 15698041 09237534
Contributors: Wheler, J.J.; Tsimberidou, A.M.; Hong, D.S.; Naing, A.; Falchook, G.S.; Fu, S.; Moulder, S.; Stephen, B.; Wen, S.; Kurzrock, R.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier

Survival of 1,181 patients in a phase I clinic: The MD Anderson Clinical Center for targeted therapy experience

Clinical Cancer Research
2012 | Journal article
DOI: 10.1158/1078-0432.CCR-11-2217
EID:

2-s2.0-84861133847

Part of ISSN: 10780432 15573265
Contributors: Wheler, J.; Tsimberidou, A.M.; Hong, D.; Naing, A.; Falchook, G.; Piha-Paul, S.; Fu, S.; Moulder, S.; Stephen, B.; Wen, S. et al.
Source: Self-asserted source
Bettzy Stephen via Scopus - Elsevier
How many people are using ORCID?